Dr. Shimosaka was very persuasive, and this first meeting was followed by a second one held in Japan that led quickly (in three days) to the signature of a joint venture contract stating that Amgen would cover the costs of the production of EPO in the USA and give Kirin the rights to market EPO for patients with chronic kidney failure in Japan, while Kirin would compensate Amgen for the knowhow on recombinant EPO and cover all the development costs in Japan. This evidence concerns the gene EPO and chronic renal failure syndrome.